BRPI0507086A - método para tratar sintomas de depressão, método monoterapêutico para tratar um paciente quanto aos sintomas de depressão, e, uso de um composto de quetiapina ou um seu sal farmaceuticamente aceitável - Google Patents
método para tratar sintomas de depressão, método monoterapêutico para tratar um paciente quanto aos sintomas de depressão, e, uso de um composto de quetiapina ou um seu sal farmaceuticamente aceitávelInfo
- Publication number
- BRPI0507086A BRPI0507086A BRPI0507086-4A BRPI0507086A BRPI0507086A BR PI0507086 A BRPI0507086 A BR PI0507086A BR PI0507086 A BRPI0507086 A BR PI0507086A BR PI0507086 A BRPI0507086 A BR PI0507086A
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- symptoms
- depression
- monotherapeutic
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
MéTODO PARA TRATAR SINTOMAS DE DEPRESSãO, MéTODO MONOTERAPêUTICO PARA TRATAR UM PACIENTE QUANTO AOS SINTOMAS DE DEPRESSãO, E, USO DE UM COMPOSTO DE QUETIAPINA OU UM SEU SAL FARMACEUTICAMENTE ACEITáVEL A presente invenção provê métodos para tratar sintomas de depressão, associados com distúrbio bipolar.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54061804P | 2004-01-30 | 2004-01-30 | |
PCT/SE2005/000094 WO2005072742A1 (en) | 2004-01-30 | 2005-01-27 | Treatment of psychoses with quetiapine antipsychotic |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0507086A true BRPI0507086A (pt) | 2007-06-19 |
Family
ID=34826230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0507086-4A BRPI0507086A (pt) | 2004-01-30 | 2005-01-27 | método para tratar sintomas de depressão, método monoterapêutico para tratar um paciente quanto aos sintomas de depressão, e, uso de um composto de quetiapina ou um seu sal farmaceuticamente aceitável |
Country Status (13)
Country | Link |
---|---|
US (2) | US20050171088A1 (pt) |
EP (1) | EP1713488A1 (pt) |
JP (1) | JP2007520488A (pt) |
KR (1) | KR20070011276A (pt) |
CN (1) | CN1913902A (pt) |
AU (1) | AU2005209142A1 (pt) |
BR (1) | BRPI0507086A (pt) |
CA (1) | CA2495361A1 (pt) |
IL (1) | IL176999A0 (pt) |
NO (1) | NO20063856L (pt) |
RU (1) | RU2006130687A (pt) |
WO (1) | WO2005072742A1 (pt) |
ZA (1) | ZA200606128B (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
JP2008526839A (ja) * | 2005-01-07 | 2008-07-24 | アストラゼネカ・アクチエボラーグ | 11−ピペラジン−1−イルジベンゾ[b,f][1,4]チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用 |
US8389510B2 (en) | 2005-11-18 | 2013-03-05 | Astrazeneca Ab | Crystalline forms |
TW200735878A (en) * | 2005-11-18 | 2007-10-01 | Astrazeneca Ab | Pharmaceutical compositions |
TWI389889B (zh) | 2006-05-09 | 2013-03-21 | Targacept Inc | (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型 |
US8017785B2 (en) | 2006-05-09 | 2011-09-13 | Astrazeneca Ab | Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine |
US8682445B2 (en) * | 2006-07-28 | 2014-03-25 | Cyberonics, Inc. | Patient management system for treating depression using an implantable medical device |
JP2010514684A (ja) * | 2006-12-20 | 2010-05-06 | アストラゼネカ・アクチエボラーグ | 化合物及びその使用 |
JP5544024B2 (ja) | 2009-12-31 | 2014-07-09 | ケムファーム・インコーポレーテッド | クエチアピンのアミノ酸結合体、その製造法及び使用法 |
ES2705233T3 (es) | 2010-03-11 | 2019-03-22 | Kempharm Inc | Conjugados de ácidos grasos de quetiapina, proceso para su fabricación y usos |
KR20130081221A (ko) | 2010-05-20 | 2013-07-16 | 아스트라제네카 아베 | 아릴 치환된 올레핀계 아민의 신규 제조 방법 |
CN102631350B (zh) * | 2012-03-29 | 2013-10-16 | 南京正科制药有限公司 | 一种富马酸喹硫平与鲁拉西酮的复方制剂 |
CN102716133A (zh) * | 2012-04-06 | 2012-10-10 | 中国人民解放军第三军医大学 | 喹硫平在制备预防和治疗自身免疫性疾病的药物中的应用 |
CN109464451B (zh) * | 2019-01-15 | 2021-07-13 | 范崇桂 | 一种治疗神经衰弱的药物及其制备方法 |
RU2717939C1 (ru) * | 2019-10-29 | 2020-03-27 | Государственное бюджетное учреждение Санкт-Петербургский научно-исследовательский институт скорой помощи им. И.И. Джанелидзе | Способ лечения интоксикационных психозов при острых отравлениях психоактивными веществами |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
US6622036B1 (en) * | 2000-02-09 | 2003-09-16 | Cns Response | Method for classifying and treating physiologic brain imbalances using quantitative EEG |
US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
CA2328197C (en) * | 1998-04-14 | 2007-11-20 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
US6960577B2 (en) * | 1998-05-22 | 2005-11-01 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
US20030027817A1 (en) * | 1998-05-29 | 2003-02-06 | Tollefson Gary Dennis | Combination therapy for treatment of bipolar disorders |
US6331571B1 (en) * | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
US6194466B1 (en) * | 1998-10-15 | 2001-02-27 | Elizabeth Marie Cottingham | Use of metformin to counteract weight gain associated with valproate and other psychotropic medications |
US20030096808A1 (en) * | 1999-03-29 | 2003-05-22 | Jon M. Miller | Substance to prevent or reverse weight gain induced by psychoactive agents |
US6489341B1 (en) * | 1999-06-02 | 2002-12-03 | Sepracor Inc. | Methods for the treatment of neuroleptic and related disorders using sertindole derivatives |
US6350773B1 (en) * | 1999-12-10 | 2002-02-26 | American Home Products Corporation | Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders |
US6599532B2 (en) * | 2000-01-13 | 2003-07-29 | Osmotica Corp. | Osmotic device containing alprazolam and an antipsychotic agent |
US6572890B2 (en) * | 2000-01-13 | 2003-06-03 | Osmotica Corp. | Osmotic device containing venlafaxine and an anti-psychotic agent |
US20020061339A1 (en) * | 2000-09-28 | 2002-05-23 | Martin Stogniew | Compositions and methods for use of extracts of rutaceae plants |
US20050054942A1 (en) * | 2002-01-22 | 2005-03-10 | Melker Richard J. | System and method for therapeutic drug monitoring |
WO2002053140A2 (en) * | 2001-01-02 | 2002-07-11 | Pharmacia & Upjohn Company | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents |
US7053092B2 (en) * | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
WO2002062346A1 (en) * | 2001-02-06 | 2002-08-15 | Astrazeneca Ab | Method of treating substance abuse with quetiapine |
US20020123490A1 (en) * | 2001-03-01 | 2002-09-05 | Pfizer Inc. | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis |
JP2004527553A (ja) * | 2001-04-26 | 2004-09-09 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 抗痙攣性誘導体と非典型的抗精神病薬を用いた共治療を含んで成る精神病性障害治療 |
US6621096B2 (en) * | 2001-05-21 | 2003-09-16 | Hewlett-Packard Develpoment Company, L.P. | Device isolation process flow for ARS system |
CA2446904A1 (en) * | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
DE10129320A1 (de) * | 2001-06-19 | 2003-04-10 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
ATE452642T1 (de) * | 2001-06-19 | 2010-01-15 | Norbert Mueller | Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen |
IL159913A0 (en) * | 2001-07-23 | 2004-06-20 | Corcept Therapeutics Inc | Methods for preventing antipsychotic-induced weight gain |
US7544681B2 (en) * | 2001-09-27 | 2009-06-09 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
GB0202900D0 (en) * | 2002-02-07 | 2002-03-27 | Laxdale Ltd | Novel formulations of drugs |
US6831077B2 (en) * | 2002-07-25 | 2004-12-14 | Comprehensive Neuroscience, Inc. | Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation |
US20040127489A1 (en) * | 2002-07-29 | 2004-07-01 | David Pickar | Novel antipsychotic combination therapies and compositions useful therein |
WO2004010932A2 (en) * | 2002-07-30 | 2004-02-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
US20050250767A1 (en) * | 2003-01-23 | 2005-11-10 | Weiner David M | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
US20040224942A1 (en) * | 2003-01-23 | 2004-11-11 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
CA2525366A1 (en) * | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
US20050171139A1 (en) * | 2003-10-07 | 2005-08-04 | Hammer Ronald P.Jr. | Treating psychotic symptoms |
JP2007509155A (ja) * | 2003-10-21 | 2007-04-12 | アルファーマ インコーポレイテッド | クエチアピンを含有する薬剤 |
US7884096B2 (en) * | 2003-12-02 | 2011-02-08 | Pharmaneuroboost N.V. | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
PT1696931E (pt) * | 2003-12-22 | 2009-06-12 | Acadia Pharm Inc | Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas |
JP2007516275A (ja) * | 2003-12-23 | 2007-06-21 | ファイザー・プロダクツ・インク | 認知増強および精神病性障害のための治療的組合せ |
MXPA06008647A (es) * | 2004-01-29 | 2006-09-04 | Pfizer Prod Inc | Combinaciones de un antipsicotico atipico y derivados azabiciclicos aminometilpiridiloximetil/bencisoxazol para tratar trastornos del sistema nervioso central. |
US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
JP2007522200A (ja) * | 2004-02-13 | 2007-08-09 | ファイザー・プロダクツ・インク | 非定型抗精神病薬とコルチコトロピン放出因子拮抗薬の治療的組合せ |
US20050181071A1 (en) * | 2004-02-18 | 2005-08-18 | Binder Michael R. | Method for the treatment of clinical depression |
TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
CA2567249A1 (en) * | 2004-04-19 | 2006-10-05 | Jds Pharmaceuticals, Llc | Lithium combinations, and uses related thereto |
EP1753460A2 (en) * | 2004-05-11 | 2007-02-21 | Pfizer Products Inc. | Combination of atypical antipsychotics and 5-ht1b receptor antagonists |
US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
US8285900B2 (en) * | 2009-02-17 | 2012-10-09 | The Board Of Regents Of The University Of Texas System | Method and apparatus for congestion-aware routing in a computer interconnection network |
-
2005
- 2005-01-26 US US11/043,622 patent/US20050171088A1/en not_active Abandoned
- 2005-01-27 AU AU2005209142A patent/AU2005209142A1/en not_active Abandoned
- 2005-01-27 JP JP2006550998A patent/JP2007520488A/ja active Pending
- 2005-01-27 CN CNA2005800036905A patent/CN1913902A/zh active Pending
- 2005-01-27 WO PCT/SE2005/000094 patent/WO2005072742A1/en active Application Filing
- 2005-01-27 KR KR1020067015308A patent/KR20070011276A/ko not_active Application Discontinuation
- 2005-01-27 EP EP05704762A patent/EP1713488A1/en not_active Withdrawn
- 2005-01-27 RU RU2006130687/14A patent/RU2006130687A/ru not_active Application Discontinuation
- 2005-01-27 BR BRPI0507086-4A patent/BRPI0507086A/pt not_active IP Right Cessation
- 2005-01-28 CA CA002495361A patent/CA2495361A1/en not_active Abandoned
-
2006
- 2006-07-20 IL IL176999A patent/IL176999A0/en unknown
- 2006-07-24 ZA ZA200606128A patent/ZA200606128B/xx unknown
- 2006-08-29 NO NO20063856A patent/NO20063856L/no not_active Application Discontinuation
-
2010
- 2010-08-17 US US12/857,897 patent/US20100311718A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2007520488A (ja) | 2007-07-26 |
ZA200606128B (en) | 2007-11-28 |
US20050171088A1 (en) | 2005-08-04 |
IL176999A0 (en) | 2006-12-10 |
RU2006130687A (ru) | 2008-03-10 |
WO2005072742A1 (en) | 2005-08-11 |
CA2495361A1 (en) | 2005-07-30 |
KR20070011276A (ko) | 2007-01-24 |
AU2005209142A1 (en) | 2005-08-11 |
CN1913902A (zh) | 2007-02-14 |
US20100311718A1 (en) | 2010-12-09 |
NO20063856L (no) | 2006-10-26 |
EP1713488A1 (en) | 2006-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0507086A (pt) | método para tratar sintomas de depressão, método monoterapêutico para tratar um paciente quanto aos sintomas de depressão, e, uso de um composto de quetiapina ou um seu sal farmaceuticamente aceitável | |
BRPI0507628A (pt) | composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto | |
BRPI0507818A (pt) | composto e métodos de inibição | |
BRPI0414082A (pt) | formas de dosagem de liberação sustentada de ziprasidona | |
MX2008006076A (es) | Metodos, composiciones y kits para el tratamiento de condiciones medicas. | |
EA200801680A1 (ru) | Производные пиримидина, применимые в качестве ингибиторов pi-3 киназы, и способы их применения | |
BRPI0512220A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
BRPI0615158A8 (pt) | composto, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição, e para preparar um composto. | |
BRPI0518360A2 (pt) | composto e sais farmaceuticamente aceitÁveis do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar um composto ou um sal farmaceuticamente aceitÁvel do mesmo | |
BRPI0508051A (pt) | derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes | |
BR0307050A (pt) | Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, sal farmaceuticamente aceitável, e, uso de um composto ou sal | |
BR0205889A (pt) | Pirazolopirimidinas como agentes tepapêuticos | |
BRPI0410418A (pt) | fenil quinolinas e seu uso como moduladores do receptor de estrogênio | |
ECSP067068A (es) | DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA PARA LA INHIBICIÓN DE b-SECRETASA | |
UY29995A1 (es) | Uso de un antagonista de cb1 para tratar efectos secundarios y síntomas negativos de la esquizofrenia | |
BRPI0509140A (pt) | processos para o tratamento de infecção por hiv | |
BRPI0411743A (pt) | método e composições para tratar doenças relacionadas a amilóides | |
BRPI0406883A (pt) | Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
RS51069B (sr) | Upotreba oksikodona za tretiranje visceralnog bola | |
BRPI0908635B8 (pt) | composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica | |
BR0309486A (pt) | Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas | |
MX2008008556A (es) | Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias. | |
TW200505829A (en) | Protease inhibitors for coronaviruses and sars-cov and the use thereof | |
AR058173A1 (es) | Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas | |
BR0113590A (pt) | 7-oxo-piridopirimidinas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A E 6A ANUIDADES |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011. |